Disease progression in HIV-1-infected viremic controllers

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 4, 2012, Pages 407-416

  Groves, Katherine C ^a,b   Bibby, David F ^a   Clark, Duncan A ^a   Isaksen, Are ^b   Deayton, Jane R ^a,b   Anderson, Jane ^c   Orkin, Chloe ^b   Stagg, Andrew J ^a   McKnight, Áine ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

activation; HIV 1; HIV 1 DNA; plasma RNA load; viremic controller

Indexed keywords

HLA DR ANTIGEN; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIGENS, CD38; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; MALE; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 84870291227     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318269c414     Document Type: Article

References (47)

1. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol. 1999;17:625-656. (Pubitemid 29241136)
2. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999;5:83-89. (Pubitemid 29051003)
3. Rodriguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296:1498-1506. (Pubitemid 44465514)
4. Deeks SG, Kitchen CMR, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942-947. (Pubitemid 39038012)
5. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859-870. (Pubitemid 29159331)
6. Liu Z, Cumberland WG, Hultin LE, et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83-92.
7. Silvestri G, Paiardini M, Pandrea I, et al. Understanding the benign nature of SIV infection in natural hosts. J Clin Invest. 2007;117:3148-3154. (Pubitemid 350096967)
8. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881-1888. (Pubitemid 37070273)
9. Bofill M, Mocroft A, Lipman M, et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS. 1996;10:827-834.
10. Sousa AE, Carneiro J, Meier-Schellersheim M, et al. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol. 2002;169:3400-3406. (Pubitemid 35013190)
11. Choudhary SK, Vrisekoop N, Jansen CA, et al. Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol. 2007;81:8838-8842. (Pubitemid 47242858)
12. Roederer M, Dubs JG, Anderson MT, et al. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest. 1995;95:2061-2066.
13. Rabin RL, Roederer M, Maldonado Y, et al. Altered representation of naive and memory CD8 T cell subsets in HIV-infected children. J Clin Invest. 1995;95:2054-2060.
14. Goujard C, Bonarek M, Meyer L, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis. 2006;42:709-715. (Pubitemid 43271388)
15. Avettand-Fenoel V, Boufassa F, Galimand J, et al. HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. J Clin Virol. 2008;42:399-404.
16. Rouzioux C, Hubert J-B, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis. 2005;192:46-55. (Pubitemid 40863856)
17. Walker BD. Elite control of HIV Infection: implications for vaccines and treatment. Top HIV Med. 2007;15:134-136.
18. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197:126-133. (Pubitemid 351263476)
19. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197:563-571. (Pubitemid 351321534)
20. Andrade A, Bailey JR, Xu J, et al. CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B 5801-positive patient with an undetectable viral load. Clin Infect Dis. 2008;46:e78-e82. (Pubitemid 351589928)
21. Mandalia S, Westrop SJ, Beck EJ, et al. Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010. PLoS One. 2012;7:e29844.
22. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antire-troviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363.
23. Dreja H, O'Sullivan E, Pade C, et al. Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. J Gen Virol. 2010;91:2794-2803.
24. Yang C, Dash BC, Simon F, et al. Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs. J Infect Dis. 2000;181:1791-1795. (Pubitemid 30387779)
25. Ndembi N, Takehisa J, Zekeng L, et al. Genetic diversity of HIV type 1 in rural eastern Cameroon. J Acquir Immune Defic Syndr. 2004;37:1641-1650. (Pubitemid 39658207)
26. Drosten C, Panning M, Drexler JF, et al. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain. Clin Chem. 2006;52:1258-1266. (Pubitemid 43956016)
27. Luo W, Yang H, Rathbun K, et al. Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J Clin Microbiol. 2005;43:1851-1857.
28. Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet. 1998;62:768-775. (Pubitemid 28194317)
29. Potter SJ, Lacabaratz C, Lambotte O, et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol. 2007;81:13904-13915. (Pubitemid 350247883)
30. Lopez M, Soriano V, Peris-Pertusa A, et al. Elite controllers display higher activation on central memory CD8 T cells than HIV patients successfully on HAART. AIDS Res Hum Retroviruses. 2011;27:157-165.
31. Emu B, Sinclair E, Favre D, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol. 2005;79:14169-14178. (Pubitemid 41552715)
32. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005;41:1053-1056. (Pubitemid 41368233)
33. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-733. (Pubitemid 27417971)
34. Dyrhol-Riise AM, Voltersvik P, Røsok BI, et al. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection. AIDS Res Hum Retroviruses. 2000;16:191-201. (Pubitemid 30111955)
35. Tilling R, Kinloch S, Goh LE, et al. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS. 2002;16:589-596. (Pubitemid 34218854)
36. Casazza JP, Betts MR, Picker LJ, et al. Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol. 2001;75:6508-6516. (Pubitemid 32578170)
37. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170. (Pubitemid 26001148)
38. Liu Z, Cumberland WG, Hultin LE, et al. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Ret-rovirol. 1998;18:332-340. (Pubitemid 28359882)
39. Okulicz JF, Grandits GA, Weintrob AC, et al. CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis. 2010;50:1187-1191.
40. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4 (+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest. 1999;103:1391-1398. (Pubitemid 29535495)
41. Cara A, Vargas J, Keller M, et al. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. Virology. 2002;292:1-5. (Pubitemid 34925832)
42. Ibanez A, Puig T, Elias J, et al. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 1999;13:1045-1049. (Pubitemid 29361394)
43. Viard J-P, Burgard M, Hubert J-B, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS. 2004;18:45-49. (Pubitemid 38402316)
44. Benito JM, Lopez M, Soriano V. The role of CD8+ T-cell response in HIV infection. AIDS Rev. 2004;6:79-88. (Pubitemid 39149446)
45. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279:2103-2106. (Pubitemid 28196353)
46. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991-998. (Pubitemid 29149355)
47. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77:11708-11717. (Pubitemid 37271669)